Tuesday, February 5, 2019

Xencor Receives $120M From Genentech

Monrovia-based biopharmaceuticals technology developer Xencor has received $120M in an upfront payment from Genentech this morning--and up to another $180M in development milestones--as part of a new deal to commercialize an immune activating cytokine based on Xencor's technology. According to Xencor, the inv

The story you have requested is only available to paid members of the socalTECH.com web site. Premium articles are restricted to paid members only. Please login in order to access this members-only content, or become a member.